Akt — also designated protein kinase B (PKB) — is a serine/threonine kinase positioned downstream of phosphatidylinositol 3-kinase (PI3K). Akt phosphorylation is the gatekeeping step for a wide set of survival, growth, and metabolic responses, and is the downstream node activated when VEGFR2 engages on vascular endothelial cells.
Definition
Akt is a family of three closely related serine/threonine kinases (Akt1, Akt2, Akt3) that sit at the centre of the PI3K-Akt-mTOR signalling cascade. Activation is a two-step process: PI3K generates the membrane lipid PIP3, which recruits Akt to the inner plasma-membrane leaflet via its pleckstrin-homology domain, and a pair of upstream kinases (PDK1 on Thr308 and mTORC2 on Ser473) then phosphorylate Akt into its active form. Active Akt phosphorylates dozens of downstream substrates including endothelial nitric oxide synthase, glycogen synthase kinase 3, the BAD apoptotic regulator, and FOXO transcription factors. The net effect varies by cell type and stimulus but routinely supports cell survival, glucose uptake, protein synthesis via mTORC1, and — in vascular endothelium — nitric oxide release.
In peptide-research contexts the cascade is most often described as VEGFR2 → PI3K → Akt → eNOS. Receptor engagement at the membrane translates to nitric oxide output within minutes, and to longer-timescale transcriptional responses on the scale of hours.
How Akt signalling is studied in peptide research
Akt activation is measured in endothelial-cell culture by Western blot for phospho-Akt (Ser473 and Thr308) alongside total Akt, and the contribution to a peptide’s observed effect is established by pharmacological inhibition (LY294002 or wortmannin upstream of Akt; MK-2206 directly on Akt). When the inhibitor blocks both Akt phosphorylation and the downstream functional outcome, the cascade is implicated as the relevant mechanism.
BPC-157 engagement of the Akt arm of the VEGFR2 cascade was documented by Hsieh et al. in vascular endothelial cell culture, with downstream eNOS activation and nitric oxide release confirmed (PMID 27847966). The nitric-oxide-system synthesis in the broader BPC-157 literature (PMID 23755725) and the major-vessel-occlusion / collateral-circulation work (PMID 35125818) extend the framing to in-vivo ischemic-stress models where the Akt-eNOS axis is the most-cited mechanism. The 2024 comprehensive review (PMID 38980576) integrates Akt-axis findings across gastric, vascular, and cytoprotective models into a unified signalling map.
Related terms
- VEGFR2
- eNOS / endothelial nitric oxide synthase
- Angiogenesis
- PI3K / phosphatidylinositol 3-kinase
- mTOR / mechanistic target of rapamycin
- Serine/threonine kinase
Compounds where Akt signalling appears in the mechanism literature
- BPC-157 — Akt phosphorylation downstream of VEGFR2 is the most-cited mechanism for the compound’s angiogenic and tissue-repair findings
- TB-500 — endothelial-cell migration and survival signalling overlap with the Akt axis, mechanistically distinct from BPC-157 but with overlapping downstream outcomes
- GHK-Cu — copper-dependent signalling intersects with Akt in fibroblast and endothelial-cell models
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
- Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World J Gastroenterol 2022;28(1):1-22. [PMID 35125818]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.